This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Patient characteristics were derived from those observed in clinical practice, based on published literature and analyses of the Healthcare Cost and Utilisation Project data and Medicare data. Clinical efficacy was derived from a randomised controlled trial (Mayer et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details). Allcause mortality was derived from the US National Vital Statistics Report. Hazard ratios for ICH survivors were the same as those used in a study evaluating the long-term outcomes of stroke patients (Samsa et al. 1999, see 'Other Publications of Related Interest' below for bibliographic details).
Methods used to judge relevance and validity, and for extracting data
The process used to identify the data was not reported. No inclusion criteria were specified for any parameters. The method used to select estimates was neither reported nor discussed.
Measure of benefits used in the economic analysis
The measure of benefit used was the quality-adjusted life-years (QALYs), although the authors also reported life-years gained. Quality of life weights, stratified by mRS scores, were obtained from a published study. The benefits were discounted at a rate of 3% per annum.
Direct costs
The direct costs included in the analysis were those to the third-party payer (e.g. Medicare). The short-term costs (defined as the first 90 days after ICH) included in the analysis were hospital costs, medical management, outpatient physician visits, durable medical equipment, and skilled nursing facilities/rehabilitation/home health care after initial hospitalisation. The latter two categories were assumed to be incurred only by those patients with severe disability (mRS 5). Hospital daily costs were estimated from a 5% sample of the Medicare database and applied to the mean length of stay observed from unpublished data derived from the randomised controlled trial used to derive efficacy data. Longterm costs (i.e. those incurred beyond 90 days) comprised all direct medical costs (such as subsequent hospitalisations), outpatient visits, durable medical equipment and any other costs incurred by the payer. The costs incurred for each state of functional recovery were determined by applying long-term cost multipliers derived from Samsa et al. 1999 , which assumed that once a patient reached a particular functional status, the costs were a function of disability.
Since the costs could be incurred over the patients' lifetime, all future costs were discounted at an annual rate of 3%. The costs were adjusted to 2003 prices using the medical component of the Consumer Price Index. The study reported the average costs. Resources and unit costs were not reported separately, although the authors did report initial length of stay stratified by mRS.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic).
Indirect Costs
No productivity losses were considered.
Currency

US dollars ($).
Sensitivity analysis
Parameter uncertainty was investigated through a series of one-way and probabilistic sensitivity analyses. The parameters analysed in the one-way sensitivity analyses were the cost multipliers, death hazard rates, hospital length of stay, distribution of patients across mRS groups, cost of medication, outpatient visits and durable equipment, quality of life weights and discount rates. The effects of varying these parameters were examined using plausible ranges from the literature, 95% confidence intervals, or by varying estimates by 20% in each direction. All model parameters were CRD COMMENTARY -Selection of comparators rFVIIa treatment was compared with standard care which, under the authors' definitions, involved treatment with placebo. It was unclear if acute treatment of ICH with a do-nothing approach, as the placebo comparator would suggest, was standard practice. You should decide if this intervention represents current practice in your own settings.
Validity of estimate of measure of effectiveness
The parameters were derived from published studies. The data do not appear to have been synthesised as each parameter in the model was derived from an individual source. The authors did not report any search methods used or inclusion criteria, nor did they provide any justification for their choice of estimates. The treatment efficacy data were derived from a Phase II clinical trial that was only powered to detect the effect of rFVIIa on haemorrhage growth. However, the authors reported that this was the only head-to-head study and the most robust available to perform an economic analysis.
Validity of estimate of measure of benefit
The estimation of health benefits (i.e. QALYs gained) was derived appropriately from a decision tree analytic model. As benefits could be incurred over the patients' lifetime, future QALYs were appropriately discounted. The quality of life weights were derived from a published study and no details of the valuation method were reported. The authors reported that quality of life weights from this study had also been used in numerous economic evaluations.
